Aurinia Pharmaceuticals Inc. Cash and Restricted Cash
Aurinia Pharmaceuticals Inc. (AUPH) had Cash and Restricted Cash of $179.83 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $179.83M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.01M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $80.21M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $73.19M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $179.83M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $41.01M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $80.21M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $73.19M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $53.00M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $66.43M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $83.43M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $37.14M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $33.41M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $64.46M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $48.88M 10-K · filed 2026-02-26 |
| 2023-09-30 | $46.40M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $81.71M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $89.00M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $94.17M 10-K · filed 2026-02-26 |
| 2022-09-30 | $86.05M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $151.63M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $132.54M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $231.90M 10-K · filed 2025-02-27 |
| 2021-09-30 | $57.59M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $121.56M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $156.59M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $272.35M 10-K · filed 2024-02-15 |
| 2020-09-30 | $248.76M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $232.41M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $274.21M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $306.02M 10-K · filed 2023-02-28 |
| 2018-12-31 | $117.97M 10-K · filed 2022-02-28 |
| 2017-12-31 | $165.63M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |